Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 6,695 shares of the life sciences company’s stock after selling 235 shares during the period. Arthur M. Cohen & Associates LLC’s holdings in Illumina were worth $864,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its position in shares of Illumina by 7.0% during the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after buying an additional 88 shares during the period. Integrated Advisors Network LLC boosted its holdings in Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after acquiring an additional 90 shares during the period. Texas Permanent School Fund Corp grew its position in Illumina by 0.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company’s stock valued at $4,507,000 after acquiring an additional 114 shares in the last quarter. Institute for Wealth Management LLC. increased its stake in Illumina by 4.6% during the second quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company’s stock worth $285,000 after purchasing an additional 119 shares during the period. Finally, Massmutual Trust Co. FSB ADV increased its stake in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research reports. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. UBS Group upped their price objective on Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. StockNews.com began coverage on Illumina in a report on Thursday, August 29th. They issued a “buy” rating for the company. TD Cowen raised Illumina from a “hold” rating to a “buy” rating and increased their price target for the company from $126.00 to $144.00 in a research report on Wednesday, August 14th. Finally, Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $120.00 to $154.00 in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $157.09.

Illumina Stock Performance

Shares of ILMN opened at $150.50 on Tuesday. The company’s 50 day simple moving average is $136.39 and its 200-day simple moving average is $122.65. The firm has a market cap of $23.97 billion, a PE ratio of -7.86 and a beta of 1.13. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $155.37. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the company earned $0.33 earnings per share. The business’s revenue was down 3.5% compared to the same quarter last year. As a group, equities analysts predict that Illumina, Inc. will post 3.62 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.